<DOC>
	<DOCNO>NCT01608724</DOCNO>
	<brief_summary>The efficacy safety study saxagliptin 5mg , daily 24 week patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>The Efficacy Safety Study Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>A multicenter , single arm , cohort study evaluate Efficacy Safety saxagliptin 5mg , daily 24 week , patient type 2 diabetes mellitus treatment naive inadequate glycaemic control metformin alone</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Diagnosed type 2 diabetes Men woman &gt; 18 year age time consent upon Visit 1 HbA1c &gt; 7.5 % â‰¤11.0 % Patients drug naive treat metformin alone stable dos least continue 8 week prior Visit 1 Drug naive patient define patient receive medical treatment diabetes ( insulin and/or oral hypo ) Pregnant breastfeed patient Insulin therapy within one year enrolment ( exception insulin therapy hospitalization use gestational diabetes ) Previous treatment DPPIV inhibitor GLP1 analogue History administration antihyperglycemic therapy ( metformin ) 8 week prior Visit 1 ( 12 week previous TZD ) Treatment systemic glucocorticoid replacement therapy Inhaled , local inject topical use glucocorticoid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Type 2 DM</keyword>
</DOC>